Two oral formulations of quetiapine: extended- -release (XR) and immediate-release (IR) tablets Review article
Article Sidebar
Main Article Content
Abstract
Quetiapine has two oral formulations: older – immediate release tablets (IR) and newer – extended release tablets (XR). Both formulations have different pharmacokinetic and clinical profiles. Quetiapine XR is taken once daily and IR twice daily. XR is associated with higher antipsychotic efficacy because is more often used in adequate dosage (> 400 mg/d). Treatment cessation due to nonadherence is less common in patients on XR. IR formulation is related to higher intensity of sedation and is commonly used as add-on therapy. The polypharmacy is typical among IR users. In many countries, quetiapine XR is administered more frequently than IR in unipolar, bipolar and psychotic disorders.
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
2. Leslie DL, Mohamed S, Rosenheck RA. Off-label use of antipsychotic medications in the Department of Veterans Affairs health care system. Psychiatric Services 2009; 60(9): 1175-1181.
3. Rowe DL. Off-label prescription of Quetiapine in psychiatric disorders. Expert Rev Neurother 2007; 7(7): 841-852.
4. Katzman MA, Brawman-Mintzer O, Reyes EB, Olausson B, Liu S, Eriksson H. Extended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trial. Int Clin Psychopharmacol 2011; 26(1): 11-24.
5. Montgomery S i in. A randomised, placebo-controlled study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5-7 grudnia 2007.
6. Rihmer Z. Antidepressive efficacy of quetiapine XR in unipolar major depression - the role of early onset of action and sleepimproving effect in decreasing suicide risk. Neuropsychopharmacol Hung 2009; 11(4): 211-215.
7. Bauer M i in. Results from a phase III study of extended release quetiapine fumarate (quetiapine XR) as add-on to antidepressants in patients with major depressive disorder (MDD). International Forum on Mood and Anxiety Disorders, Budapeszt, Węgry, 5-7 grudnia 2007.
8. Hallinen T, Soini EJ, Granstro O, Ovaskainen Y, Leinonen E, Koponen HJ, Hanninen K. Differential use of extended and immediate release quetiapine: a retrospective registry study of Finnish inpatients with schizophrenia spectrum and bipolar disorders. BMJ Open 2012; 2: e000915.
9. Eriksson L, Hallerbäck T, Jørgensen L, Carlborg A. Use of quetiapine XR and quetiapine IR in clinical practice for hospitalized patients with schizophrenia: a retrospective study. Ther Adv Psychopharmacol 2012; 2(6): 217-226.
10. Kapur S, Zipursky R, Jones C, Shammi CS, Remington G, Seeman P. A positron emission tomography study of quetiapine in schizophrenia: a preliminary finding of an antipsychotic effect with only transiently high dopamine D2 receptor occupancy. Arch Gen Psychiatry 2000; 57: 553-559.
11. Nord M, Nyberg S, Brogren J, Jucaite A, Halldin C, Farde L. Comparison of D2 dopamine receptor occupancy after oral administration of quetiapine fumarate immediate-release and extended-release formulations in healthy subjects. International Journal of Neuropsychopharmacology 2011; 14: 1357-1366.
12. Riesenberg RA, Baldytcheva I, Datto C. Self-reported sedation profile of quetiapine extended-release and quetiapine immediate- release during 6-day initial dose escalation in bipolar depression: a multicenter, randomized, double-blind, phase IV study. Clinical Therapeutics 2012; 34(11): 2202-2211.